What Researchers Did
Researchers conducted a systematic review to examine the incidence, risk factors, etiology, and management of visual loss associated with biostimulator injectables.
What They Found
The review identified at least 11 published cases of visual impairment from vascular occlusion with calcium hydroxylapatite (CaHA), two with poly-L-lactic acid (PLLA), two with poly-D,L-lactic acid (PDLLA)-carboxy-methylcellulose (CMC), and one with PDLLA-hyaluronic acid (HA). Polycaprolactone (PCL) had no reported cases of blindness, though one case of facial artery embolism was noted.
What This Means for Canadian Patients
Patients considering biostimulator injectables should be aware of the potential, albeit rare, risk of visual loss due to vascular occlusion. It is crucial to discuss these risks with a qualified practitioner and ensure they are knowledgeable about facial anatomy and emergency management protocols.
Canadian Relevance
This systematic review does not have a direct Canadian connection.
Study Limitations
A limitation of this systematic review is its reliance on published case reports, which may not capture all instances of visual loss or reflect the true incidence.